Wave Pharma (WVE): Price/Earnings to Growth Ratio
High clinical trial expenses for RNA drugs are creating financial pressure for Wave Life Sciences (WVE), yet the company's current PEG valuation demonstrates investment potential. The value of 0.00 determines the current magnitude of this metric. These concerns are mitigated by the PRISM AI platform for developing sterile therapies, as well as a strategic alliance with Takeda and GSK, which accelerates product commercialization and optimizes business margins.
Wave Life Sciences (WVE) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- issuer book value statistics:
- debt obligations and liquidity statistics:
Debt to Capital Wave Life Sciences|WVE - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital wavelifesciences.com|WVE - Company Debts|Debts to Net Assets Wave Life Sciences Corp|WVE - Company Long-Term Debts|Company Current Liabilities Wave Life Sciences|Interim Coverage Ratio wavelifesciences.com
- net income and valuation ratios data:
WVE - Net Profit|Expected Net Profit Wave Life Sciences|WVE - Price to Earnings Ratio|Price to Future Earnings Ratio Wave Pharma|WVE - PEG Multiple|Enterprise Value to EBITDA Ratio Wave Life Sciences Corp|WVE - Operating profit EBITDA|Net earnings per one share for the last twelve months Wave Life Sciences|WVE - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months wavelifesciences.com|WVE - Net earnings per share growth this year|Expected earnings per share growth for next year Wave Life Sciences
Fundamental company analysis:WVE, Wave Life Sciences Ltd
The PEG ratio determines the fairness of an asset's market value by comparing the current P/E multiple with the growth rate of earnings per share. Analyzing the price-to-earnings-to-EPS growth ratio reveals the undervaluation of Wave Life Sciences (WVE), where the robotization of oligonucleotide synthesis and the automation of RNA chain screening should ensure an exponential acceleration of business development, justifying the company's investment attractiveness.
Competing companies
TEM (Tempus AI, Inc) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Qiagen Group QGEN|Isis Pharmaceuticals - Price/Earnings to Growth Ratio|Repligen Corporation - PEG Multiple|Growth-Adjusted Market Cap to Net Income aviditybiosciences.com RNA|CRSP: PEG Multiple|Market Cap to Earnings and Growth Ratio WGS (GeneDx Holdings)|RARE (Ultragenyx Pharma) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Beam Tx BEAM|Price/Earnings to Growth Multiple SRPT (Sarepta Therapeutics, Inc.)|TWST (twistbioscience.com) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio 10x Genomics TXG|Growth-Adjusted Market Cap to Net Income Intellia Therapeutics Inc (NTLA)|Stoke - PEG Multiple|BioLife (BLFS) - Price/Earnings to Growth Multiple|MAZE: PEG Multiple|SION - Growth-Adjusted Market Cap to Net Income|PRME (Prime Medicine) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Taysha Gene Therapies Inc TSHA|Price/Earnings to Growth Ratio uniQure Corp (QURE)|MeiraGTx Corp - Growth-Adjusted P/E Ratio|PEG Multiple RGNX (REGENXBIO Inc.)|SLDB - Price/Earnings to Growth Multiple|Ocugen - PEG Multiple|Price to Earnings Adjusted for Growth Rate Pacific Biosciences of California, Inc.|Benitec (BNTC) - Price/Earnings to Growth Ratio|DSGN - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple RCKT|Price/Earnings to Growth Multiple 4dmoleculartherapeutics.com (FDMT)|Price/Earnings to Growth Multiple LXEO (Lexeo Therapeutics)|Price/Earnings to Growth Ratio KRRO (korrobio.com)|PEG Multiple EDIT (Editas)|Silence Therapeutics Corp (SLN) - Price to Earnings Adjusted for Growth Rate|ProQR Therapeutics NV - PEG Multiple|CDXS (Codexis, Inc.) - Growth-Adjusted P/E Ratio|Sangamo Therapeutics, Inc. (SGMO) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio NAUT|MGX (Metagenomi, Inc) - PEG Multiple|PEG Multiple Precision BioSciences Inc.|Price/Earnings to Growth Multiple GBIO (Generation Bio Co.)|Price/Earnings to Growth Multiple boundlessbio.com BOLD|PEG Multiple XCUR (Exicure)|PEG Multiple Imunon Inc IMNN|PHIO: Price/Earnings to Growth Multiple|MBIO: Price/Earnings to Growth Ratio|RNAZ: PEG Multiple|Price to Earnings Adjusted for Growth Rate Bionano Genomics (BNGO)|Price/Earnings to Growth Multiple APDN|BLUE: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio ImmunoPrecise Antibodies (IPA)|Price/Earnings to Growth Ratio OMGA (Omega Therapeutics Corp)|PEG Multiple OMIC (Singular Genomics Systems)|Growth-Adjusted Market Cap to Net Income regulusrx.com (RGLS)|Syros Pharmaceuticals, Inc. - PEG Multiple|Market Cap to Earnings and Growth Ratio TBIO|TCON: PEG Multiple|Price to Earnings Adjusted for Growth Rate Unity Biotechnology, Inc (UBX)
